Two cases of acute respiratory failure following SARS-CoV-2 vaccination in post-COVID-19 pneumonia.
Tomohiro BandoReoto TakeiYoshikazu MutohHajime SasanoYasuhiko YamanoToshiki YokoyamaToshiaki MatsudaKensuke KataokaTomoki KimuraYasuhiro KondohPublished in: Respirology case reports (2022)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is a very effective method of preventing infection and is recommended for people having recovered from coronavirus disease 2019 (COVID-19). In this novel case report, we describe two patients with post-COVID-19 pneumonia who experienced acute respiratory failure and new bilateral ground-glass opacities several days after receiving SARS-CoV-2 vaccination. Both patients were treated with methylprednisolone pulse therapy and recovered from the disease successfully. Indeed, post-COVID-19 patients can gain benefits from the vaccine, but vaccination at the early stage of recovery from COVID-19 might be a risk for certain populations. These cases highlight a potential association between vaccination, interstitial lung disease and worsening of post-COVID-19 pneumonia. Further investigation and research examining the relationship between the timing of SARS-CoV-2 vaccination and potential risks in post-COVID-19 patients is recommended.
Keyphrases
- sars cov
- respiratory failure
- respiratory syndrome coronavirus
- coronavirus disease
- extracorporeal membrane oxygenation
- mechanical ventilation
- early stage
- case report
- interstitial lung disease
- end stage renal disease
- newly diagnosed
- systemic sclerosis
- ejection fraction
- blood pressure
- acute respiratory distress syndrome
- liver failure
- chronic kidney disease
- prognostic factors
- intensive care unit
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- climate change
- hepatitis b virus
- risk assessment
- drug induced
- locally advanced
- neoadjuvant chemotherapy